



Peptides

Volume 88, February 2017, Pages 189-195

Spinal neuropeptide expression and neuropathic behavior in the acute and chronic phases after spinal cord injury: Effects of progesterone administration

María F. Coronel ^a, Marcelo J. Villar ^b, Pablo R. Brumovsky ^b , Susana L. González ^{a, c} [Show more](#)<https://doi.org/10.1016/j.peptides.2017.01.001>[Get rights and content](#)

Highlights

- **Neuropathic pain** elicited by **spinal cord injury** (SCI) is refractory to treatment.
- SCI induces changes in the spinal expression of **Galanin**, NPY and their **receptors**.
- These **neuropeptide** systems may be involved in an endogenous protective response.
- **Progesterone** (PG) prevents the injury-induced changes in neuropeptide expression.
- PG prevents **allodynia** and emerges as an attractive strategy to prevent chronic pain.

Abstract

Patients with spinal cord injury (SCI) develop chronic pain that severely compromises their quality of life. We have previously reported that progesterone (PG), a neuroprotective steroid, could offer a promising therapeutic strategy for neuropathic pain. In the present study, we explored temporal changes in the expression of the neuropeptides galanin and tyrosine (NPY) and their receptors (GalR1 and GalR2; Y1R and Y2R, respectively) in the injured spinal cord and evaluated the impact of PG administration on both neuropeptide systems and neuropathic

behavior. Male rats were subj

subcutaneous injections of PG or vehicle, and were evaluated for signs of mechanical and thermal allodynia. Real time PCR was used to determine relative mRNA levels of neuropeptides and receptors, both in the acute (1 day) and chronic (28 days) phases after injury. A significant increase in Y1R and Y2R expression, as well as a significant downregulation in GalR2 mRNA levels, was observed 1 day after SCI. Interestingly, PG early treatment prevented Y1R upregulation and resulted in lower NPY, Y2R and GalR1 mRNA levels. In the chronic phase, injured rats showed well-established mechanical and cold allodynia and significant increases in galanin, NPY, GalR1 and Y1R mRNAs, while maintaining reduced GalR2 expression. Animals receiving PG treatment showed basal expression levels of galanin, NPY, GalR1 and Y1R, and reduced Y2R mRNA levels. Also, and in line with previously published observations, PG-treated animals did not develop mechanical allodynia and showed reduced sensitivity to cold stimulation. Altogether, we show that SCI leads to considerable changes in the spinal expression of galanin, NPY and their associated receptors, and that early and sustained PG administration prevents them. Moreover, our data suggest the participation of galaninergetic and NPYergic systems in the plastic changes associated with SCI-induced neuropathic pain, and further supports the therapeutic potential of PG- or neuropeptide-based therapies to prevent and/or treat chronic pain after central injuries.

[< Previous](#)

[Next >](#)

Abbreviations

CGRP, Calcitonin gene related peptide; CycB, cyclophilin B; CTL, control animals; DRGs, dorsal root ganglia; HX, hemisected animals; X + P, Ghemisected animals treated with progesterone; NPY, neuropeptide Y; PCR, polymerase chain reaction; PG, progesterone; SCI, spinal cord injury

Keywords

Allodynia; Chronic pain; Galanin; Neuropeptide tyrosine; Progesterone; Spinal cord

[Recommended articles](#)

[Citing articles \(6\)](#)

[View full text](#)

© 2017 Elsevier Inc. All rights reserved.

ELSEVIER

About ScienceDirect

Terms and conditions



Privacy policy



Get Access

Share

Export

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [use of cookies](#).

Copyright © 2019 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

